



## **Kurma Partners announces that QIAGEN enters into agreement to acquire STAT-Dx, a company of its Kurma Biofund 1 portfolio**

**January 31, 2018** – Kurma Partners announced today that Qiagen entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries. Kurma has been the lead investor of the series'B financing in April 2013 and has continued to support all following financing round.

Subject to the successful completion of defined development activities by STAT-Dx, QIAGEN has agreed to acquire all shares of STAT-Dx for approximately \$147 million in cash and additional payments of up to about \$44 million based on the achievement of regulatory and commercial milestones. The acquisition is expected to be completed in the second quarter of 2018.

Please find the Press Release issued by Qiagen announcing the transaction by clicking on the following link: [https://corporate.qiagen.com/newsroom/press-releases/2018/20180131\\_stat\\_dx](https://corporate.qiagen.com/newsroom/press-releases/2018/20180131_stat_dx)

### **About STAT-Dx**

Founded in 2010 in Barcelona, Spain, and backed by a consortium of leading international healthcare investors including Kurma Partners, Idinvest Partners, Gilde Healthcare Ysios Capital, Boehringer Ingelheim Venture Fund, Caixa Capital Risc and Axis, STAT-Dx is focused on the development, manufacturing and commercialization of "Closer to Care" diagnostic solutions in areas where fast and accurate diagnostic results are crucial, such as infectious diseases and critical care. The DiagCORE® system is a versatile, easy-to-use platform that consolidates molecular and immunoassay techniques in a single device. For more information, visit [www.stat-dx.com](http://www.stat-dx.com).

### **About QIAGEN**

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2017, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found at <http://www.qiagen.com>.

### **About Kurma Partners**

Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, notably through Kurma Biofund I and II, Kurma Diagnostics and strategic partnerships with prestigious European research and medical institutions.

[www.kurmapartners.com](http://www.kurmapartners.com)

Press contacts: NewCap - Nicolas Merigeau: [+33\(0\)1 44 71 94 98](tel:+330144719498) – [nmerigeau@newcap.fr](mailto:nmerigeau@newcap.fr)